Back to School: How biopharma can reboot drug development. Access exclusive analysis here

July 24 Company Quick Takes: Samsung's Humira biosimilar gets FDA approval; plus Intra-Cellular, Sage and more

FDA approves Samsung's Humira biosimilar
Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will begin marketing the drug in

Read the full 393 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers